Bionime Corp (4737) - Net Assets
Based on the latest financial reports, Bionime Corp (4737) has net assets worth NT$1.76 Billion TWD (≈ $55.31 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$5.70 Billion ≈ $179.72 Million USD) and total liabilities (NT$3.95 Billion ≈ $124.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4737 total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.76 Billion |
| % of Total Assets | 30.78% |
| Annual Growth Rate | 6.5% |
| 5-Year Change | -15.44% |
| 10-Year Change | -32.13% |
| Growth Volatility | 26.6 |
Bionime Corp - Net Assets Trend (2009–2025)
This chart illustrates how Bionime Corp's net assets have evolved over time, based on quarterly financial data. Check 4737 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Bionime Corp (2009–2025)
The table below shows the annual net assets of Bionime Corp from 2009 to 2025. For live valuation and market cap data, see Bionime Corp stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.76 Billion ≈ $55.31 Million |
-7.06% |
| 2024-12-31 | NT$1.89 Billion ≈ $59.51 Million |
-5.23% |
| 2023-12-31 | NT$1.99 Billion ≈ $62.80 Million |
-4.20% |
| 2022-12-31 | NT$2.08 Billion ≈ $65.55 Million |
+0.21% |
| 2021-12-31 | NT$2.08 Billion ≈ $65.41 Million |
+0.26% |
| 2020-12-31 | NT$2.07 Billion ≈ $65.24 Million |
+1.17% |
| 2019-12-31 | NT$2.05 Billion ≈ $64.49 Million |
+2.70% |
| 2018-12-31 | NT$1.99 Billion ≈ $62.79 Million |
-4.07% |
| 2017-12-31 | NT$2.08 Billion ≈ $65.46 Million |
-19.68% |
| 2016-12-31 | NT$2.59 Billion ≈ $81.50 Million |
+1.77% |
| 2015-12-31 | NT$2.54 Billion ≈ $80.08 Million |
+88.68% |
| 2014-12-31 | NT$1.35 Billion ≈ $42.44 Million |
+25.82% |
| 2013-12-31 | NT$1.07 Billion ≈ $33.73 Million |
+6.96% |
| 2012-12-31 | NT$1.00 Billion ≈ $31.54 Million |
-7.75% |
| 2011-12-31 | NT$1.09 Billion ≈ $34.19 Million |
+6.75% |
| 2010-12-31 | NT$1.02 Billion ≈ $32.02 Million |
+58.59% |
| 2009-12-31 | NT$640.89 Million ≈ $20.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bionime Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 223.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$673.32 Million | 38.58% |
| Other Components | NT$1.24 Billion | 71.00% |
| Total Equity | NT$1.75 Billion | 100.00% |
Bionime Corp Competitors by Market Cap
The table below lists competitors of Bionime Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LAUNCH TECH CO. H YC-01
F:LAN
|
$136.39 Million |
|
Silver X Mining Corp
V:AGX
|
$136.41 Million |
|
Baiksan
KO:035150
|
$136.46 Million |
|
Caribou Biosciences Inc
NASDAQ:CRBU
|
$136.46 Million |
|
Cape Industries Ltd
KQ:064820
|
$136.34 Million |
|
Owlet Inc
NYSE:OWLT
|
$136.31 Million |
|
Ajiya Bhd
KLSE:7609
|
$136.28 Million |
|
Yg Plus Inc
KO:037270
|
$136.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bionime Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,879,978,000 to 1,745,406,000, a change of -134,572,000 (-7.2%).
- Net loss of 180,277,000 reduced equity.
- New share issuances of 5,377,000 increased equity.
- Other factors increased equity by 40,328,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-180.28 Million | -10.33% |
| Share Issuances | NT$5.38 Million | +0.31% |
| Other Changes | NT$40.33 Million | +2.31% |
| Total Change | NT$- | -7.16% |
Book Value vs Market Value Analysis
This analysis compares Bionime Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.86x to 2.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$14.51 | NT$56.00 | x |
| 2010-12-31 | NT$24.86 | NT$56.00 | x |
| 2011-12-31 | NT$22.02 | NT$56.00 | x |
| 2012-12-31 | NT$20.34 | NT$56.00 | x |
| 2013-12-31 | NT$22.10 | NT$56.00 | x |
| 2014-12-31 | NT$27.58 | NT$56.00 | x |
| 2015-12-31 | NT$44.51 | NT$56.00 | x |
| 2016-12-31 | NT$36.84 | NT$56.00 | x |
| 2017-12-31 | NT$31.49 | NT$56.00 | x |
| 2018-12-31 | NT$31.18 | NT$56.00 | x |
| 2019-12-31 | NT$31.62 | NT$56.00 | x |
| 2020-12-31 | NT$31.13 | NT$56.00 | x |
| 2021-12-31 | NT$30.96 | NT$56.00 | x |
| 2022-12-31 | NT$30.70 | NT$56.00 | x |
| 2023-12-31 | NT$29.50 | NT$56.00 | x |
| 2024-12-31 | NT$28.06 | NT$56.00 | x |
| 2025-12-31 | NT$25.70 | NT$56.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bionime Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.81%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 3.27x
- Recent ROE (-10.33%) is below the historical average (5.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 21.10% | 14.42% | 1.05x | 1.39x | NT$71.15 Million |
| 2010 | 13.39% | 11.23% | 0.94x | 1.27x | NT$34.41 Million |
| 2011 | 16.51% | 12.13% | 0.52x | 2.63x | NT$70.60 Million |
| 2012 | 3.41% | 2.38% | 0.40x | 3.63x | NT$-65.95 Million |
| 2013 | 8.40% | 5.76% | 0.35x | 4.23x | NT$-17.14 Million |
| 2014 | 4.03% | 3.56% | 0.33x | 3.46x | NT$-80.41 Million |
| 2015 | 3.89% | 6.14% | 0.35x | 1.80x | NT$-155.40 Million |
| 2016 | 6.91% | 10.27% | 0.37x | 1.80x | NT$-79.89 Million |
| 2017 | 7.20% | 8.22% | 0.42x | 2.11x | NT$-58.15 Million |
| 2018 | 6.43% | 6.38% | 0.44x | 2.30x | NT$-71.09 Million |
| 2019 | 5.20% | 4.89% | 0.49x | 2.16x | NT$-98.00 Million |
| 2020 | 3.02% | 3.74% | 0.37x | 2.17x | NT$-144.13 Million |
| 2021 | 4.22% | 4.73% | 0.41x | 2.21x | NT$-119.52 Million |
| 2022 | 4.39% | 4.12% | 0.44x | 2.40x | NT$-116.22 Million |
| 2023 | 0.31% | 0.35% | 0.33x | 2.67x | NT$-192.39 Million |
| 2024 | -6.77% | -6.58% | 0.33x | 3.08x | NT$-315.21 Million |
| 2025 | -10.33% | -9.81% | 0.32x | 3.27x | NT$-354.82 Million |
Industry Comparison
This section compares Bionime Corp's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,830,163,889
- Average return on equity (ROE) among peers: 15.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bionime Corp (4737) | NT$1.76 Billion | 21.10% | 2.25x | $136.35 Million |
| St.Shine Optical Co Ltd (1565) | $3.89 Billion | 41.14% | 0.59x | $146.13 Million |
| Maxigen Biotech Inc (1783) | $851.32 Million | 7.06% | 0.39x | $112.59 Million |
| SciVision Biotech Inc (1786) | $1.08 Billion | 3.72% | 0.04x | $116.46 Million |
| Bioteque (4107) | $1.62 Billion | 13.32% | 0.24x | $247.80 Million |
| Chi Sheng Chemical (4111) | $1.05 Billion | 7.76% | 0.41x | $56.27 Million |
| BenQ Medical Technology (4116) | $1.09 Billion | 6.10% | 0.54x | $54.27 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.55 Billion | 17.99% | 0.55x | $173.61 Million |
| Vizionfocus Inc. (4771) | $2.04 Billion | 27.62% | 1.19x | $336.64 Million |
| Formosa Optical Technology Co Ltd (5312) | $2.30 Billion | 15.61% | 0.85x | $168.03 Million |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offers blood glucose monitoring devices and systems under the RIGHTEST… Read more